AR033308A1 - Uso de escitalopram enantiomericamente puro - Google Patents

Uso de escitalopram enantiomericamente puro

Info

Publication number
AR033308A1
AR033308A1 ARP020101612A ARP020101612A AR033308A1 AR 033308 A1 AR033308 A1 AR 033308A1 AR P020101612 A ARP020101612 A AR P020101612A AR P020101612 A ARP020101612 A AR P020101612A AR 033308 A1 AR033308 A1 AR 033308A1
Authority
AR
Argentina
Prior art keywords
disorders
disorder
treatment
enantiomerically pure
scitalopram
Prior art date
Application number
ARP020101612A
Other languages
English (en)
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR033308A1 publication Critical patent/AR033308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
ARP020101612A 2001-05-01 2002-05-02 Uso de escitalopram enantiomericamente puro AR033308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01

Publications (1)

Publication Number Publication Date
AR033308A1 true AR033308A1 (es) 2003-12-10

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101612A AR033308A1 (es) 2001-05-01 2002-05-02 Uso de escitalopram enantiomericamente puro

Country Status (25)

Country Link
US (7) US20040198809A1 (enExample)
EP (1) EP1385503A1 (enExample)
JP (1) JP2004527551A (enExample)
KR (2) KR20100012089A (enExample)
CN (1) CN1509169A (enExample)
AR (1) AR033308A1 (enExample)
AT (1) AT10974U1 (enExample)
BG (1) BG108379A (enExample)
BR (1) BR0208283A (enExample)
CA (1) CA2445843A1 (enExample)
CZ (1) CZ20033267A3 (enExample)
EA (1) EA200301195A1 (enExample)
HR (1) HRP20030744A2 (enExample)
HU (1) HUP0400054A3 (enExample)
IL (1) IL158031A0 (enExample)
IS (1) IS6954A (enExample)
ME (1) MEP5908A (enExample)
MX (1) MXPA03008777A (enExample)
NO (1) NO20034538D0 (enExample)
PL (1) PL367480A1 (enExample)
SK (1) SK14612003A3 (enExample)
UA (1) UA82828C2 (enExample)
WO (1) WO2002087566A1 (enExample)
YU (1) YU85303A (enExample)
ZA (1) ZA200307102B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
ES2515092T3 (es) * 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
EA200601641A1 (ru) * 2004-03-05 2006-12-29 Х. Лундбекк А/С Кристаллическая композиция, содержащая оксалат эсциталопрама
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2086509A1 (en) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) * 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
MY157192A (en) * 2007-08-03 2016-05-13 Richter Gedeon Nyrt Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP2248808B1 (en) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
EP3294337B1 (en) * 2015-05-13 2024-12-18 Arvid Carlsson Research AB Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
UA62984C2 (en) * 1997-11-11 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SK285719B6 (sk) * 1998-10-20 2007-07-06 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukty
EP1173431B2 (en) * 1999-04-14 2009-08-26 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途

Also Published As

Publication number Publication date
BR0208283A (pt) 2004-03-09
US20040198810A1 (en) 2004-10-07
US20040198811A1 (en) 2004-10-07
MEP5908A (xx) 2010-02-10
NO20034538L (no) 2003-10-09
BG108379A (bg) 2004-11-30
IL158031A0 (en) 2004-03-28
EP1385503A1 (en) 2004-02-04
US20040192764A1 (en) 2004-09-30
CZ20033267A3 (en) 2004-06-16
JP2004527551A (ja) 2004-09-09
UA82828C2 (en) 2008-05-26
KR20040030609A (ko) 2004-04-09
HUP0400054A3 (en) 2007-03-28
CN1509169A (zh) 2004-06-30
US20040192765A1 (en) 2004-09-30
US20040198809A1 (en) 2004-10-07
HRP20030744A2 (en) 2005-06-30
KR20100012089A (ko) 2010-02-05
MXPA03008777A (es) 2004-02-12
WO2002087566A1 (en) 2002-11-07
AT10974U1 (de) 2010-02-15
YU85303A (sh) 2006-05-25
CA2445843A1 (en) 2002-11-07
IS6954A (is) 2003-09-15
US20080004338A1 (en) 2008-01-03
US20040192766A1 (en) 2004-09-30
NO20034538D0 (no) 2003-10-09
EA200301195A1 (ru) 2004-04-29
HUP0400054A2 (hu) 2004-04-28
PL367480A1 (en) 2005-02-21
SK14612003A3 (sk) 2004-04-06
ZA200307102B (en) 2004-09-13

Similar Documents

Publication Publication Date Title
AR033308A1 (es) Uso de escitalopram enantiomericamente puro
NO20100333L (no) Behandling av nevrotiske forstyrrelser
ATE410157T1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
WO2004004641A3 (en) PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
PE20040924A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
Kim et al. Influence of self-esteem and social support on the depression stati of some clinical nurses
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
AR047715A1 (es) Combinaciones de analepticos y antdepresivos
MY140179A (en) Analeptic and antidepressant combinations
HUP0300354A2 (hu) HIV immunadjuváns terápia
TW200509895A (en) Analeptic and antidepressant combinations
TW200509894A (en) Analeptic and antidepressant combinations
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
ATE333274T1 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
NO20061167L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon
Catherine I am a nurse
Invernizzi et al. Antidepressant efficacy in the treatment of dysthymia
EA200801080A1 (ru) Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
MX2025000820A (es) SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS
Stepanchikova et al. Hepatitis C: molecular-biological and medico-social aspects of the problem. Public internet resource

Legal Events

Date Code Title Description
FB Suspension of granting procedure